Genelux (GNLX) Competitors $3.34 -0.13 (-3.75%) Closing price 04:00 PM EasternExtended Trading$3.33 -0.01 (-0.30%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNLX vs. ATYR, SIGA, TRML, CGEM, MBX, RZLT, KMDA, TERN, RGNX, and SVRAShould you be buying Genelux stock or one of its competitors? The main competitors of Genelux include aTyr Pharma (ATYR), Siga Technologies (SIGA), Tourmaline Bio (TRML), Cullinan Therapeutics (CGEM), MBX Biosciences (MBX), Rezolute (RZLT), Kamada (KMDA), Terns Pharmaceuticals (TERN), REGENXBIO (RGNX), and Savara (SVRA). These companies are all part of the "pharmaceutical products" industry. Genelux vs. Its Competitors aTyr Pharma Siga Technologies Tourmaline Bio Cullinan Therapeutics MBX Biosciences Rezolute Kamada Terns Pharmaceuticals REGENXBIO Savara Genelux (NASDAQ:GNLX) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment. Is GNLX or ATYR more profitable? aTyr Pharma's return on equity of -87.09% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets GeneluxN/A -93.04% -74.17% aTyr Pharma N/A -87.09%-64.77% Does the media favor GNLX or ATYR? In the previous week, aTyr Pharma had 6 more articles in the media than Genelux. MarketBeat recorded 8 mentions for aTyr Pharma and 2 mentions for Genelux. Genelux's average media sentiment score of 0.94 beat aTyr Pharma's score of 0.59 indicating that Genelux is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive aTyr Pharma 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend GNLX or ATYR? Genelux presently has a consensus target price of $17.75, indicating a potential upside of 431.44%. aTyr Pharma has a consensus target price of $20.20, indicating a potential upside of 246.48%. Given Genelux's stronger consensus rating and higher probable upside, equities analysts plainly believe Genelux is more favorable than aTyr Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20aTyr Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Which has stronger earnings and valuation, GNLX or ATYR? Genelux has higher earnings, but lower revenue than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenelux$10K12,611.84-$29.87M-$0.88-3.80aTyr Pharma$230K2,255.96-$64.02M-$0.81-7.20 Which has more risk & volatility, GNLX or ATYR? Genelux has a beta of -0.34, indicating that its stock price is 134% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Do insiders and institutionals believe in GNLX or ATYR? 37.3% of Genelux shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 9.3% of Genelux shares are owned by company insiders. Comparatively, 3.7% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryaTyr Pharma beats Genelux on 8 of the 15 factors compared between the two stocks. Get Genelux News Delivered to You Automatically Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNLX vs. The Competition Export to ExcelMetricGeneluxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$131.03M$3.07B$5.70B$9.51BDividend YieldN/A2.36%4.69%4.01%P/E Ratio-3.8021.0428.0720.05Price / Sales12,611.84284.46448.5799.42Price / CashN/A42.7636.2258.56Price / Book4.398.378.665.87Net Income-$29.87M-$55.19M$3.25B$258.55M7 Day Performance0.30%5.89%4.20%2.23%1 Month Performance13.61%17.63%10.82%12.76%1 Year Performance73.96%5.09%34.70%19.36% Genelux Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNLXGenelux1.2316 of 5 stars$3.34-3.7%$17.75+431.4%+59.9%$131.03M$10K-3.8010Positive NewsAnalyst ForecastGap UpATYRaTyr Pharma2.1682 of 5 stars$5.53+4.3%$20.20+265.3%+187.6%$492.17M$230K-6.8353Gap UpHigh Trading VolumeSIGASiga Technologies1.9892 of 5 stars$6.86+1.3%N/A-27.4%$490.08M$138.72M10.2440News CoverageUpcoming EarningsOptions VolumeTRMLTourmaline Bio1.9085 of 5 stars$18.96+5.5%$49.33+160.2%+13.8%$486.99MN/A-5.9144News CoveragePositive NewsCGEMCullinan Therapeutics2.0273 of 5 stars$7.87+2.2%$30.00+281.2%-59.0%$464.41MN/A-2.7030Positive NewsMBXMBX Biosciences2.1326 of 5 stars$13.87+6.4%$37.50+170.4%N/A$463.59MN/A0.0036News CoverageRZLTRezolute2.5489 of 5 stars$5.32+1.1%$11.83+122.4%+26.5%$454.97MN/A-4.6340News CoverageAnalyst RevisionKMDAKamada4.1156 of 5 stars$7.78+0.4%$13.00+67.1%+33.7%$447.39M$167.24M26.83360News CoveragePositive NewsTERNTerns Pharmaceuticals3.9741 of 5 stars$5.11+4.3%$15.63+205.8%-30.1%$446.31MN/A-4.6940RGNXREGENXBIO4.1758 of 5 stars$8.70+0.2%$31.63+263.5%-33.1%$436.39M$83.33M-2.80370News CoveragePositive NewsSVRASavara1.8468 of 5 stars$2.51+5.0%$5.60+123.1%-43.5%$433.83MN/A-5.2320Positive News Related Companies and Tools Related Companies aTyr Pharma Alternatives Siga Technologies Alternatives Tourmaline Bio Alternatives Cullinan Therapeutics Alternatives MBX Biosciences Alternatives Rezolute Alternatives Kamada Alternatives Terns Pharmaceuticals Alternatives REGENXBIO Alternatives Savara Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNLX) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNLX Stock Alerts